Global Bloodstream Infection Testing Market Size Study & Forecast, by Product (Reagents & Consumables, Instruments), by Sample Type (Whole Blood, Blood Culture), by Technology (PCR, Mass Spectroscopy, In Situ Hybridization, Others), by End-use (Hospitals

Global Bloodstream Infection Testing Market Size Study & Forecast, by Product (Reagents & Consumables, Instruments), by Sample Type (Whole Blood, Blood Culture), by Technology (PCR, Mass Spectroscopy, In Situ Hybridization, Others), by End-use (Hospitals & Diagnostic Centers, Custom Laboratory Service Providers, Others), and Regional Analysis, 2023-2030

Global Bloodstream Infection Testing Market is valued at approximately USD 689.13 million in 2022 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2023-2030. Bloodstream infection testing, also known as blood culture testing, is a medical diagnostic procedure that is used to detect the presence of microorganisms, such as bacteria, fungi, and sometimes viruses, in a patient's bloodstream. It is a critical diagnostic tool in clinical medicine for identifying and managing sepsis, a severe and potentially life-threatening condition that occurs when the body's response to infection causes harm to its own tissues and organs. This plays a vital role in investigating the bacteria and pathogens accountable for bloodstream infections. There is a heightened risk of infectious diseases spreading particularly in densely populated regions with limited hygiene practices, posing a significant threat to public health. This presents a challenge for public health management, necessitating efficient diagnostic approaches to identify and contain these infections. The global rise in infectious diseases and the growing awareness and focus on infection control stand out as key drivers propelling the market growth during the estimated period.

In addition, the rise in the number of blood donation campaigns is playing a major role in supporting the market growth on a global scale. Governments around the world are implementing initiatives to reduce the incidence of healthcare-associated infections. These initiatives are driving the demand for bloodstream infection testing in hospitals and other healthcare settings. For instance, in August 2022, The U.S. Department of Health and Human Services (HHS) unveiled an initiative to boost blood and plasma donations. This initiative focuses on raising public consciousness about the significance of blood and plasma donations and fostering a culture of consistent contributions among Americans. Also, in November 2021, the Emirates Health Services (EHS) launched a Blood Donation Campaign with the objective of fostering community engagement and nurturing a culture of generosity. This initiative seeks to increase awareness about the significance of blood donation and to address the requirements of patients. Thus, this initiative promotes blood donation which further leads to an emphasis on infection control and prevention in healthcare settings, especially in the wake of healthcare-associated infections. Initiatives to curb the overuse and misuse of antibiotics, which are closely tied to the management of bloodstream infections, promote the use of targeted testing. Moreover, the rise in the development of rapid point-of-care testing solutions, as well as the increasing use of invasive medical devices presents various lucrative opportunities over the forecast years. However, the high diagnosis cost and lower investments in underdeveloped countries are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Bloodstream Infection Testing Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increased disposable income, the presence of well-established healthcare infrastructure, favorable reimbursement policies, and a growing number of strategic endeavors and product launches by major industry players. Additionally, the surge in demand for rapid diagnostic tests, as well as growing awareness of healthcare-associated infection is further propelling the market demand across the region. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The growing investment in technological advancements and increasing number of government initiatives are significantly propelling the market demand across the region. Also, the increasing prevalence of chronic diseases, the rising aging population, along with shift towards patient-centered care and personalized medicine are further promoting the regional market expansion.

Major market players included in this report are:
BioMérieux SA
Becton, Dickinson and Company
Cepheid.
Seegene Inc.
T2 Biosystems, Inc.
F. Hoffmann-La Roche Ltd
Siemens Healthcare GmbH
Luminex Corporation.
Bruker
Accelerate Diagnostics, Inc.

Recent Developments in the Market:
 In October 2022, BD, a renowned global medical technology firm, partnered with Magnolia Medical Technologies, Inc., in a commercial agreement. This agreement is focusing on aiding U.S. hospitals in minimizing blood culture contamination, elevating the precision of testing, and, ultimately, enhancing clinical outcomes.
 In July 2022, T2 Biosystems, Inc., a prominent player in the early detection of antibiotic resistance genes and pathogens causing sepsis, was granted approval by the U.S. Food and Drug Administration (FDA) for its T2Lyme Panel. This panel allows healthcare providers to expedite appropriate treatment for patients, thereby mitigating the potential adverse effects of treatment and reducing antibiotic overuse.

Global Bloodstream Infection Testing Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Sample Type, Technology, End-use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Reagents & Consumables
Instruments

By Sample Type:
Whole Blood
Blood Culture

By Technology:
PCR
Mass Spectroscopy
In Situ Hybridization
Others

By End-use:
Hospitals & Diagnostic Centers
Custom Laboratory Service Providers
Academic & Research Institutes
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
BioMérieux SA
Becton, Dickinson and Company
Cepheid.
Seegene Inc.
T2 Biosystems, Inc.
F. Hoffmann-La Roche Ltd
Siemens Healthcare GmbH
Luminex Corporation.
Bruker
Accelerate Diagnostics, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.